VisMederi announces the successful qualification of a standardized, high-throughput Luminescence Serum Bactericidal Assay (L-SBA) — a key milestone in supporting the evaluation of next-generation Shigella vaccines.
This achievement reflects the strength of an outstanding international collaboration involving VisMederi, the University of Siena, the GSK Vaccines Institute for Global Health (GVGH), Hogrefe Consulting Inc., the Gates Medical Research Institute, and LimmaTech Biologics AG.
Together, we are advancing innovative tools that accelerate vaccine development and help protect the world’s most vulnerable populations.
Read here: https://lnkd.in/dJEPkVTi
